Dr Axel Ullrich wins 2009 Paul Janssen Award
This article was originally published in Scrip
Executive Summary
The 2009 Dr Paul Janssen Award, worth $100,000, has been presented to Dr Axel Ullrich for pioneering the development of genomics-based therapeutics, including Genentech/Roche's HER2-targeted Herceptin (trastuzumab), which is used to treat HER2-positive breast cancer, and Pfizer's multi-targeted kinase inhibitor sunitinib malate (Sutent), which is used to treat renal cell carcinoma.